Philippe Moingeon Selected Research

OM 197-MP-AC

12/2007

A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Moingeon Research Topics

Disease

27	Hypersensitivity (Allergy) 01/2022 - 01/2006
8	Seasonal Allergic Rhinitis (Hay Fever) 09/2017 - 03/2005
6	Asthma (Bronchial Asthma) 01/2019 - 12/2007
4	Neoplasms (Cancer) 01/2022 - 05/2002
4	Inflammation (Inflammations) 01/2021 - 09/2008
4	Respiratory Hypersensitivity 09/2017 - 01/2008
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2021
3	Pneumonia (Pneumonitis) 01/2021 - 08/2007
3	Food Hypersensitivity (Food Allergy) 01/2017 - 03/2010
3	Colorectal Neoplasms (Colorectal Cancer) 07/2003 - 05/2002
2	Communicable Diseases (Infectious Diseases) 01/2022 - 10/2003
2	Rheumatic Diseases (Rheumatism) 10/2021 - 01/2021
2	Anaphylaxis (Anaphylactic Shock) 01/2020 - 01/2011
2	Allergic Rhinitis 01/2017 - 03/2015
2	Rhinitis 01/2015 - 02/2012
2	Melanoma (Melanoma, Malignant) 12/2005 - 01/2005
2	Infections 01/2005 - 10/2003
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Cytokine Release Syndrome 01/2021
1	COVID-19 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Disease Progression 10/2020
1	Eczema 01/2012
1	Dust Mite Allergy 01/2010
1	Carcinoma (Carcinomatosis) 01/2005

Drug/Important Bio-Agent (IBA)

22	AllergensIBA 01/2020 - 01/2006
20	VaccinesIBA 01/2020 - 05/2002
7	AntigensIBA 01/2020 - 05/2002
6	Immunoglobulin E (IgE)IBA 01/2017 - 01/2012
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2015
5	OvalbuminIBA 09/2017 - 08/2007
4	Biological ProductsIBA 01/2022 - 10/2003
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2006
3	Interleukin-10 (Interleukin 10)IBA 10/2020 - 01/2008
3	TabletsIBA 01/2017 - 04/2012
2	InterferonsIBA 10/2021 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2020
2	ragweed pollenIBA 06/2016 - 10/2015
2	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2012 - 09/2008
1	Drug CombinationsIBA 01/2022
1	AlarminsIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Interferon-alpha (Interferon Alfa)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 09/2017
1	alpha-2-HS-GlycoproteinIBA 09/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Complementary DNA (cDNA)IBA 10/2015
1	Peptide Hydrolases (Proteases)FDA Link 10/2015
1	RNA (Ribonucleic Acid)IBA 10/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015
1	Nasal SpraysIBA 01/2015
1	calcium phosphateIBA 10/2012
1	Aluminum Hydroxide (Algeldrate)FDA Link 10/2012
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 10/2012
1	Interleukin-12 (IL 12)IBA 10/2012
1	P-2 (P 2)IBA 01/2012
1	Arthropod VenomsIBA 01/2011
1	Dermatophagoides pteronyssinus antigen p 1IBA 01/2010
1	Dermatophagoides pteronyssinus antigen p 2IBA 01/2010
1	OM 197-MP-ACIBA 12/2007
1	Interleukin-5 (Interleukin 5)IBA 08/2007
1	maltodextrinIBA 08/2007
1	Biomarkers (Surrogate Marker)IBA 01/2006
1	HLA-A1 Antigen (HLA A1 Antigen)IBA 12/2005
1	Peptides (Polypeptides)IBA 12/2005
1	Recombinant ProteinsIBA 03/2005
1	MART-1 AntigenIBA 01/2005
1	EpitopesIBA 01/2005
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2005
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2003
1	Epithelial Cell Adhesion MoleculeIBA 07/2003
1	Neoplasm Antigens (Tumor Antigens)IBA 07/2003
1	ALVAC vaccineIBA 05/2002
1	Combined VaccinesIBA 05/2002

Therapy/Procedure

17	Immunotherapy 01/2022 - 05/2006
3	Therapeutics 01/2022 - 09/2008
1	Precision Medicine 01/2022
1	Nebulizers and Vaporizers (Inhaler) 01/2015
1	Injections 01/2011
1	Sublingual Administration 12/2007
1	Drug Therapy (Chemotherapy) 10/2003
1	Intravenous Administration 07/2003